Fulgent Genetics

NASDAQ:FLGT

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information.

CEO Interviews
Featured Articles and Interviews
Press Releases

Fulgent Reports Second Quarter 2025 Financial Results

Fulgent Genetics Launches Picture Genetics

INNspired
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

INN Disclaimer: This profile is sponsored by Fulgent Genetics ( NASDAQ:FLGT ). This profile provides information which was sourced by the Investing News Network (INN) and approved by Fulgent Genetics in order to help investors learn more about the company. Fulgent Genetics is a client of INN. The company's campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. In exchange for publishing services rendered by INN on behalf of Fulgent Genetics named herein, including the promotion by INN of Fulgent Genetics in any content on the INN website, the INN receives from Fulgent Genetics annual cash compensation of typically up to two hundred and fifty thousand dollars. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Fulgent Genetics and seek advice from a qualified investment advisor.

The Conversation (0)

Interactive Chart

×